Autopsy report · NCT00508430

ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy

“An independent DMC determined continuation was unlikely to demonstrate a statistically significant advantage of ASP8825 over placebo on the primary endpoint”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 199 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Astellas Pharma Inc

Sponsor type

Industry

Conditions

Diabetic Neuropathies

Interventions

ASP8825; Placebo

Participants

199

Sites

8

Countries

Japan

Trials that died the same way

• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
  “Results of a planned interim analysis did not show significant effects for any of the 3 AIN dose regimens versus placebo on any primary or secondary endpoint” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.